Lupin receives US FDA nod to market Voriconazole tablets for fungal treatment

New Delhi: Drug major Lupin has received final approval from the US health regulator to market Voriconazole tablets, used for the treatment of fungal infections, in the American market.


"Its US subsidiary, Gavis Pharmaceuticals LLC(collectively Lupin), has received final approval for its Voriconazole Tablets, 50 mg and 200 mg, and Voriconazole Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration (USFDA) to market a generic equivalent of PF Prism CV's Vfend Tablets," the company said in a BSE filing.

It further said, the company shall commence promoting the products in the US shortly.

According to IMS MAT March 2016 sales data, Vfend tablets, 50 mg and 200 mg, had sales of $92.8 million while Vfend Oral Suspension, 40 mg/mL, had US sales of $15.9 million.

In tandem with the sluggish broad market sentiment, Lupin shares at 1.10 pm traded nearly 0.8 percent lower at Rs 1,438.10.

Updated Date: Jun 06, 2016 13:12 PM

Also Watch

IPL 2018: Royal Challengers Bangalore eye revival against Chennai Super Kings as 'Cauvery Derby' comes back to life
  • Thursday, April 26, 2018 In the Kanjarbhat community, a campaign against 'virginity tests' is slowly gaining ground
  • Tuesday, April 24, 2018 It's A Wrap: Beyond the Clouds stars Ishaan Khatter, Malavika Mohanan in conversation with Parul Sharma
  • Monday, April 9, 2018 48 hours with Huawei P20 Pro: Triple camera offering is set to redefine smartphone imaging
  • Monday, April 16, 2018 Rajyavardhan Singh Rathore interview: Sports can't be anyone's fiefdom, we need an ecosystem to nurture raw talent